Absci Corp Dossier
Qualitative Analysis
Business overview
Absci Corp is a clinical-stage biopharmaceutical company that integrates generative artificial intelligence (AI) models with synthetic biology and high-throughput wet-lab automation to design and optimize antibody therapeutics. The company operates an 'Integrated Drug Creation' platform designed to compress the traditional drug discovery timeline from 4-6 years down to approximately two years. Absci monetizes its platform through dual pathways: collaborative partner programs with major pharmaceutical and biotech firms (such as Merck and Owkin) that yield upfront fees and milestone payments, and an internal pipeline of wholly-owned therapeutic assets designed for clinical development and potential out-licensing.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic collaboration with Advanced Micro Devices (AMD) to scale Absci's AI Drug Creation platform using AMD Instinct accelerators and ROCm software.
Expected impact: Enhanced performance, speed, and capacity of Absci's generative AI models for de novo antibody design.
Prioritizing investments to advance wholly-owned internal therapeutic programs, specifically lead asset ABS-201 (anti-PRLR) and ABS-101 (anti-TL1A), from AI design to clinical proof-of-concept.
Expected impact: Establishing clinical validation of AI-designed antibodies and creating high-value assets for potential out-licensing.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Aims to optimize and scale Absci's AI Drug Creation platform using AMD's high-performance computing hardware and software stack.
Terms: $20 million strategic equity investment in Absci by AMD concurrent with the collaboration in January 2025.